Entrada Therapeutics, Inc. has reported promising results from its Phase 1/2 clinical study of ENTR-601-45, a treatment aimed at Duchenne muscular dystrophy (DMD). The findings are particularly noteworthy as they indicate the potential effectiveness of ENTR-601-45 in improving dystrophin production in participants with specific genetic mutations.
On October 14, 2026, the company issued a press release detailing the positive topline data from Cohort 1 of the ELEVATE-45-201 study. This study is designed to evaluate the safety and efficacy of ENTR-601-45 in ambulatory participants aged four to 20 with DMD who are amenable to exon 45 skipping. Entrada's announcement marks a significant milestone in the development of treatments for this severe genetic disorder.
Company Background
Entrada Therapeutics, Inc. operates in the pharmaceutical preparations industry, specifically focusing on innovative therapies for genetic diseases. The company is publicly traded under the ticker TRDA on the Nasdaq exchange. Founded in Delaware, Entrada is classified under the SIC code 2834, which pertains to pharmaceutical preparations.
What the Filing Says
The recent SEC filing reveals that the topline results from Cohort 1 of the ELEVATE-45-201 study showed a mean increase of 0.10% in dystrophin production in participants receiving ENTR-601-45, compared to a decrease in the placebo group. The study enrolled eight participants who received either the treatment or a placebo, administered intravenously over a series of doses.
"Favorable safety and tolerability with ENTR-601-45 at the 5 mg/kg dose were noted," the filing states, highlighting that the most common treatment-emergent adverse event was headache. Importantly, there were no serious safety concerns reported, and all participants continued into the open-label extension of the study.
Impact
The positive results from this study may significantly impact patients suffering from DMD, providing hope for improved treatment options. Additionally, these findings could influence the pharmaceutical industry, particularly companies focused on genetic therapies. The success of ENTR-601-45 may prompt competitors to accelerate their own research and development efforts in similar therapeutic areas.
What's Next
Entrada is set to continue its clinical research, with plans to report data from Cohort 2, which is currently undergoing dosing at 10 mg/kg, in the first half of 2027. Data from Cohort 3, which will evaluate doses up to 15 mg/kg, is expected to follow. The company’s ongoing commitment to advancing its clinical trials reflects its dedication to finding effective treatments for DMD.
For more details, refer to the SEC filing with accession number 0001689375-26-000057.